View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 July 2025 in which we reassessed the appropriateness of the ratings in the context of the rel...

Pierre FerraguÊ
  • Pierre FerraguÊ

Are Biotechnologies heading towards a zero-shot future? Key insights f...

We kicked off our AI Transforming Industries series last week. We had a fantastic conversation with Mike Nally, CEO of Generate:Biomedicines on how AI is reshaping biotech and drug discovery.

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Amgen Inc. - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Key facts and statistics - LTM June 2024

A summary company profile, detailing Amgen’s business operations and financial highlights.

Amgen Inc. - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Update following outlook revision to stable from negative

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by its unresolved IRS tax disputes.

Moody's Ratings affirms Amgen's Baa1 ratings; revises outlook to stabl...

Moody's Ratings (Moody's) affirmed the ratings of Amgen Inc. (Amgen) including the Baa1 senior unsecured notes rating, (P)Baa1 senior unsecured shelf rating, (P)Baa1 senior unsecured medium term note program rating, and Prime-2 commercial paper rating. At the same time, we revised Amgen's outlook to...

Amgen Inc. - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Near-term focus on pipeline execution, integration of Hori...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by unresolved IRS tax disputes

Moody's announces completion of a periodic review of ratings of Amgen ...

Moody's Ratings has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 March 2024 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant...

Amgen Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Key facts and statistics - LTM June 2023

A summary company profile, detailing Amgen Inc’s business operations and financial highlights.

Amgen Inc. - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Steady performance continues while pending Horizon acquisi...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by higher financial leverage associated with the pending Horizon acquisition.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Amgen Inc. - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...

Moody's: Amgen's and Horizon Therapeutics' ratings unaffected by FTC r...

Moody's Investors Service (Moody's) commented that the ratings and outlooks of Amgen Inc. ("Amgen") and Horizon Therapeutics USA Ltd, a subsidiary of Horizon Therapeutics plc (collectively "Horizon") are unaffected by the announcement that the US Federal Trade Commission is seeking to block Amgen's ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch